Drugs Monitor, Page 15

(06 Jan 2021) Corticosteroids- early use in critically ill patients associated with lower mortality

January 11, 2021

Early corticosteroids are associated with lower mortality in critically ill patients with COVID-19: a cohort study https://doi.org/10.1186/s13054-020-03422-3 This is a nationwide, prospective, multicenter, observational, cohort study in critically ill adult patients with COVID-19 admitted into Intensive Care Units (ICU) in… Continue reading "(06 Jan 2021) Corticosteroids- early use in critically ill patients associated with lower mortality"

(06 Jan 2021)Anakinra- in combination with TCZ improved prognosis

January 11, 2021

Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study https://doi.org/10.1007/s11739-020-02600-z A retrospective observational cohort study was carried out involving 143 patients with severe COVID-19 pneumonia and moderate… Continue reading "(06 Jan 2021)Anakinra- in combination with TCZ improved prognosis"

(05 Jan 2021) Heparin- LMWH was associated with lower all-cause in-hospital mortality

January 6, 2021

The Association of Low Molecular Weight Heparin Use and In-hospital Mortality Among Patients Hospitalized with COVID-19 https://doi.org/10.1007/s10557-020-07133-3 Overall, 525 patients with COVID-19 enrolled with a median age of 64 years (IQR 19), and 49.33% men. Among these, 120 (22.86%) were… Continue reading "(05 Jan 2021) Heparin- LMWH was associated with lower all-cause in-hospital mortality"

(04 Jan 2021) Enoxaprin- 60% reduction of mortality with higher doses

January 6, 2021

Increasing dosages of low-molecular-weight heparin in hospitalized patients with Covid-19 https://doi.org/10.1007/s11739-020-02585-9 Of 278 patients with Covid-19, 127 received prophylaxis with high enoxaparin doses and 151 with standard dosage. At 21 days, the incidence rate of death and clinical deterioration were… Continue reading "(04 Jan 2021) Enoxaprin- 60% reduction of mortality with higher doses"

(01 Jan 2021) Tocilizumab- TCZ with or without favipiravir can effectively improved the pulmonary inflammation of COVID-19 patients

January 2, 2021

Tocilizumab combined with favipiravir in the treatment of COVID-19: A multicenter trial in a small sample size https://doi.org/10.1016/j.biopha.2020.110825 This was a multicenter trial (ChiCTR2000030894 and NCT04310228) in adults with COVID-19. Patients were randomly assigned (3:1:1) to a 14-day combination of… Continue reading "(01 Jan 2021) Tocilizumab- TCZ with or without favipiravir can effectively improved the pulmonary inflammation of COVID-19 patients"

(29 Dec 2020) Heparin- LMWH was associated with a reduced risk of 30-day mortality

January 2, 2021

Role of Low-Molecular-Weight Heparin in Hospitalized Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Pneumonia: A Prospective Observational Study https://doi.org/10.1093/ofid/ofaa563 Among 315 patients with SARS-CoV-2 pneumonia, 70 (22.2%) died during hospital stay. The composite endpoint was achieved by 114 (36.2%)… Continue reading "(29 Dec 2020) Heparin- LMWH was associated with a reduced risk of 30-day mortality"

(29 Dec 2020) Nitazoxanide- early nitazoxanide therapy was safe and reduced viral load significantly

January 2, 2021

Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial https://doi.org/10.1183/13993003.03725-2020 NCT04552483- In a multicenter, randomised, double-blind, placebo-controlled trial, adult patients presenting up to 3 days after onset of Covid-19 symptoms (dry cough, fever, and/or fatigue) were enrolled. After… Continue reading "(29 Dec 2020) Nitazoxanide- early nitazoxanide therapy was safe and reduced viral load significantly"

(29 Dec 2020) Baricitinib- additional loading dose of baricitinib revealed better clinical outcome

January 2, 2021

Additional baricitinib loading dose improves clinical outcome in COVID-19 https://doi.org/10.1515/med-2021-0010 This prospective case-control study enrolled 37 adult patients where 17 patients (control) received baricitinib at 4 mg oral daily dose and 20 patients (case) received an additional single 8 mg… Continue reading "(29 Dec 2020) Baricitinib- additional loading dose of baricitinib revealed better clinical outcome"

(24 Dec 2020) Tocilizumab- 60.0% patients demonstrated clinical improvement

January 2, 2021

Tocilizumab in the Management of COVID-19: A Preliminary Report https://doi.org/10.1016/j.amjms.2020.11.005 A retrospective, observational study was conducted on hospitalized adults who received intravenous tocilizumab for COVID-19 between March 23, 2020 and April 10, 2020. Most patients were male (66.7%), Hispanic (63.3%)… Continue reading "(24 Dec 2020) Tocilizumab- 60.0% patients demonstrated clinical improvement"

(23 Dec 2020) Hydroxychloroquine- HCQ was associated with a slower viral clearance in mild to moderateCOVID-19 patients

December 28, 2020

Hydroxychloroquine is associated with slower viral clearance in clinical COVID-19 patients with mild to moderate disease https://doi.org/10.1097/MD.0000000000023720 Thirty-four confirmed COVID-19 patients completed the study. Nineteen (55.9%) patients presented with symptoms, and 14 (41.2%) had pneumonia. Only 21 (61.8%) patients received… Continue reading "(23 Dec 2020) Hydroxychloroquine- HCQ was associated with a slower viral clearance in mild to moderateCOVID-19 patients"